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It is known that the glutamatergic pathways are hyperfunctioning during alcohol withdrawal syndrome.
It has been demonstrated that hyperfunctioning of this system causes a great damage to the superior cor-
tical activity, the ability to concentrate and the control of impulses. Recent studies show that the cations
zinc and magnesium modulate the glutamatergic function, reducing it to non-toxic levels, yet not reduc-
ing it to the point of depriving this neurotransmitter of its normal activity. New perspectives of treatment
focus on the modulation of this system, having, as a result, reestablishment of impulse control abilities,
damage prevention to the hippocampus and the amygdala and prevention of future relapses.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
The cognitive impairments observed in alcohol dependence
syndrome are well documented in several studies [1–4]. Some
functions, such as verbal ﬂuency, working memory and frontal
functions are so severely impaired that they can be compared with
the cognitive impairment caused by Alzheimer’s disease [1]. Sev-
eral relapses and the consequent withdrawal syndromes might
cause more intense cognitive impairment. The reason why it hap-
pens has not been clearly established.
On the other hand, it is known that glutamatergic pathways are
hyperfunctioning during alcohol withdrawal syndrome, especially
through NMDA receptors, which are responsible for maintaining,
in normal conditions, individual ability of performing complex
planning, task-resolution performance and behavior restraint. This
hyperactivity stemming fromNMDA receptors causes great calcium
inﬂux, increasing the activity of nitrous oxide synthase (one of the
main enzymes activated by transduction), which in turn increases
the excitotoxic activity and accelerates the production of free radi-
cals of oxygen, and the resulting in irreversible neural death [5–7]. It
has been proved that the hyperfunctioning of the glutamatergic
system causes great damage to the superior cortical activity, the
ability to concentrate and the control of impulses [6–8].
Recent studies show that low doses of zinc and magnesium cat-
ions modulate the glutamatergic function, reducing it to non-toxic
levels, yet not reducing it to the point of depriving this neurotrans-
mitter of its normal function [9,10]..L. Prior), galduroz@psico
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Zinc (Zn) is an important body element which, in the central
nervous system (CNS), is concentrated mainly in the hippocampus,
in the subiculum of the dentate gyrus and in the accessory olfac-
tory bulb [11]. It is found mainly in glutamatergic neurons, in spe-
ciﬁc pathways whose nuclei are in the putamen, caudatum and
amygdala, with efferences to the cortex, striatum and hippocam-
pus [12].
Fig. 1 shows its main metabolic functions: (1) blockage of gluta-
mate on the synaptic cleft, (2) storage of glutamate in the pre-
synaptic neuron, so as to regulate its distribution, and (3) action
on several pre- and post-synaptic intracellular proteins, such as en-
zymes, second messengers and transcription factors which favor
the synthesis of glutamatergic receptors (NMDA and KA), growth
factors and mitosis inducers (neurogenesis) [12–14]. Fig. 2 shows
possible roles of zinc in reducing symptoms in withdrawal.
Magnesium
Magnesium is the fourth most abundant ion in human metabo-
lism, and has particular importance in the central nervous system
as a cofactor in many enzymes, in the DNA synthesis, as inhibitor of
voltage-dependent calcium channels and the release of neuro-
transmitters [6,15]. Its role is as a negative modulator of the NMDA
receptors, competing with glutamate in its binding site and inhib-
iting the nitrous oxide synthase enzyme, important in the neural
transmission in glutamatergic pathways [16,17].
Magnesium can provoke a modest stimulation for the gabaergic
system and is capable of reducing the oxidative stress in the brain,
lowering the concentration of neurotoxic substances stimulating
Fig. 1. Neurochemical effects of the lack of zinc in the central nervous system, mimicking the abstinence-like syndrome effects on neural function. As described, lack of zinc
may cause increase and lack of control in cellular oxidative activity, increase in glutamatergic activity, through NMDA receptors [12,14].
Fig. 2. Possible effects of zinc supplementation, according to evidence.
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as an ameliorator in mid-crisis alcohol abstinence [5–7].
The role of magnesium would stand out not only in the NMDA
receptor, but also in the inhibition of the NO-synthase and calcium
dependent channels, lowering effects for action potential ﬁring,
also mitigating certain symptoms (as seen in Fig. 3).Hypothesis
Although the relapse during the treatment of alcoholism is seen
as inevitable by some authors [18], the damage caused to neurons
by excessive stimulation by glutamate and lack of inhibition of the
NMDA receptors may be decisive factors for the maintenance of
dependence in the long term. Therefore, the use of zinc and mag-nesium to treat abstinence syndrome is a hypothesis worth
considering.New perspectives
The unstable mechanisms of action of pure NMDA receptors’
agonists and antagonists have shown irregular and conﬂicting re-
sults in literature, which shows, as a consensus, that antagonists
are effective in rats and humans in relation to alcohol and nicotine
dependence [19,20], and agonists mainly in cocaine dependence.
Neither has apparent effect in opioid dependence.
Even though many different symptoms are involved in each
substance’s pathway targets, we believe that the NMDA receptors’
effects are a common factor in developing tolerance, dependence
Fig. 3. Possible effects in magnesium supplementation (Mg) [9,10].
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potentiation of the glutamatergic system by zinc and magnesium
synthesize the beneﬁcial effects of the chemical compounds de-
scribed above, without their side effects and downsides
Both ions (magnesium and zinc) have the great advantage of
inhibiting immediate excitotoxic activity of glutamate in its iono-
tropic receptor, and, at the same time, stimulating metabolic
changes in protein synthesis and second messengers, which will
stabilize and adapt glutamatergic activity to its normal and neces-
sary rate. This shows their regulatory nature in the central nervous
system.
It is suspected that, since both compounds act in different sites
inside and outside neurons, and by different mechanisms in the
same pathways, one can potentialize and increase the other’s ef-
fect, with very few registered side effects (mainly diarrhea) and
low costs.Conﬂict of interest
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